Sign in
Knowstox

Fundamentals snapshot

BriaCell Therapeutics Corp.

BCTX · NCM · Healthcare · Biotechnology

Current price

$3.39

52-week range

$2.60 - $13.09

Market cap

$29.60M

One-glance verdict

Not enough data

Fair value unavailable

Not enough cash-flow history to value this one with our method.

Balance sheet

Healthy

-1,216.77x Concerning

Net cash $20.54M. Interest coverage shows how many times profit covers the interest bill.

What this company does

BriaCell Therapeutics Corp.

BriaCell Therapeutics Corp. is developing new ways to treat cancer by using the body's own immune system. Their main product is a treatment for advanced breast cancer that is currently in the final stages of testing to see if it works. This matters because if approved, it could offer a new option for patients with limited choices.

Price history

How the share price has moved

—
Loading price history…

Earnings history

Last 8 quarters — what happened

Click any quarter to read the call summary and what the numbers say.

Free cash flow by quarter (oldest to newest)
FY2026 Q3 $-7.15M FY2026 Q4 $-5.96M
Revenue —
Net income $-12.32M
Diluted EPS 0.95
Operating cash flow $-5.96M
Free cash flow $-5.96M
Revenue —
Net income $-7.16M
Diluted EPS -0.99
Operating cash flow $-7.02M
Free cash flow $-7.15M
Revenue —
Net income $-7.22M
Diluted EPS -2.58
Operating cash flow $-7.97M
Free cash flow —
Revenue —
Net income $-8.20M
Diluted EPS -4.35
Operating cash flow $-7.70M
Free cash flow —
Revenue —
Net income $-8.09M
Diluted EPS -58.00
Operating cash flow $-8.13M
Free cash flow —
Revenue —
Net income $-6.13M
Diluted EPS -1.64
Operating cash flow $-7.16M
Free cash flow —
Revenue —
Net income $-6.29M
Diluted EPS -2.33
Operating cash flow $-5.92M
Free cash flow —
Revenue —
Net income $-5.80M
Diluted EPS -0.22
Operating cash flow $-6.96M
Free cash flow —

Is it cheap or expensive?

Fair value — vs current price $3.39

We couldn't calculate a fair value right now.

lower confidence

We estimate the cash this business should generate over the next 10 years and beyond, then convert it to today's money for a fair value per share, in its trading currency. Cautious, middle and optimistic growth cases give a range. Not for banks/insurers.

Is it drowning in debt?

Healthy

Net cash $20.5M - more cash than debt. Interest coverage -1216.8x.

Net debt $-20.54M
Interest coverage -1,216.77x

BriaCell Therapeutics Corp.'s profit covers its interest bill about 0.0 times over. which is weaker than most peers shown here and 3 peers sit below 1x, which is the danger zone where profit does not fully cover the interest bill.

Healthy
Worse cushion Baseline Better cushion
BCTX BASELINE BriaCell Therapeutics Corp.

Total debt $0.00 Interest coverage -1,216.77x This is the baseline the peer rows are being compared against.

-1,216.77x
HURA TuHURA Biosciences, Inc.

Total debt $9.18M Interest coverage -43.64x Neither company has much profit cushion over interest right now.

-43.64x
KZIA Kazia Therapeutics Limited

Total debt $67.27K Interest coverage -197.46x Neither company has much profit cushion over interest right now.

-197.46x
OKUR OnKure Therapeutics, Inc.

Total debt $790.00K Interest coverage -7,868.75x Neither company has much profit cushion over interest right now.

-7,868.75x

What you should know

The case for and against BCTX

0 Rewards 2 Risks

Rewards

Risks

  • Return on equity was -214.8% last year — the company lost money on shareholders' equity.
  • Insider ownership is only 0.1% (peer median: 15.4%).

The numbers

All the key metrics, grouped by purpose

Tap any ? icon to learn what it means.

Valuation

How expensive the stock looks

P/E (TTM)
—
Forward P/E
-8.69x
P/B
1.80x
P/S
—
EV/EBITDA
-0.28x
PEG ratio
—

Profitability

How much profit each dollar creates

Gross margin
0.0%
Operating margin
0.0%
Net margin
0.0%
ROE
-214.8%
ROA
-99.6%

Health

Liquidity and balance-sheet strength

Debt / equity
—
Current ratio
2.76x
Quick ratio
2.57x
Total debt
$0.00
Total cash
$20.54M

Growth

How the business has been compounding

Revenue TTM
$0.00
Revenue 5Y CAGR
—
EPS TTM
-6.97
EPS 5Y CAGR
—

Cash flow

How much cash the business throws off

Operating CF TTM
$-28.65M
Free CF TTM
$-28.78M
FCF margin
—

Dividend

Shareholder payout

Yield
0.0%
Payout ratio
0.0%
Last ex-div date
—